AnaptysBio Inc announced that its subsidiary First Tracks Bio has received approval from the Nasdaq Stock Exchange and will officially initiate "When-Issued Trading" of its shares on April 6, 2026. The trading symbol is set as "Trax".

This important development marks a key step in the company's capitalization process, laying the foundation for its subsequent official listing. The "deferred trading" mechanism allows investors to conduct conditional trading before the official issuance of shares, providing the market with a price discovery function. First Tracks Bio's choice of this trading method reflects the market's positive expectations for its development prospects. Professional analysts note that such trading arrangements typically signal that the company is about to enter a substantive stage in the capital market.